Published in Antioxid Redox Signal on February 06, 2014
Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. Nat Commun (2015) 1.57
Neurodegeneration with brain iron accumulation: update on pathogenic mechanisms. Front Pharmacol (2014) 1.09
Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration. Biomed Res Int (2014) 1.00
Regional siderosis: a new challenge for iron chelation therapy. Front Pharmacol (2013) 0.96
Advances in non-dopaminergic treatments for Parkinson's disease. Front Neurosci (2014) 0.93
The iron regulatory capability of the major protein participants in prevalent neurodegenerative disorders. Front Pharmacol (2014) 0.91
Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson's Disease. Antioxid Redox Signal (2016) 0.89
Oxidative Stress in Neurodegenerative Diseases. Mol Neurobiol (2015) 0.89
Motor and cognitive deficits in aged tau knockout mice in two background strains. Mol Neurodegener (2014) 0.88
Eryptosis as a marker of Parkinson's disease. Aging (Albany NY) (2014) 0.86
Biometals and their therapeutic implications in Alzheimer's disease. Neurotherapeutics (2015) 0.85
Iron chelation and multiple sclerosis. ASN Neuro (2014) 0.84
Iron accumulation confers neurotoxicity to a vulnerable population of nigral neurons: implications for Parkinson's disease. Mol Neurodegener (2014) 0.83
Cp/Heph mutant mice have iron-induced neurodegeneration diminished by deferiprone. J Neurochem (2015) 0.81
Ceruloplasmin activity and iron chelation treatment of patients with Parkinson's disease. BMC Neurol (2015) 0.81
World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. World J Methodol (2014) 0.80
Iron and Oxidative Stress in Parkinson's Disease: An Observational Study of Injury Biomarkers. PLoS One (2016) 0.79
Role of iron in neurodegenerative diseases. J Neural Transm (Vienna) (2016) 0.79
Quantitative Susceptibility Mapping in Parkinson's Disease. PLoS One (2016) 0.79
Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review. Biomed Res Int (2014) 0.79
Lateral Asymmetry and Spatial Difference of Iron Deposition in the Substantia Nigra of Patients with Parkinson Disease Measured with Quantitative Susceptibility Mapping. AJNR Am J Neuroradiol (2016) 0.78
Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases. World J Methodol (2014) 0.78
The value of magnetic resonance imaging as a biomarker for amyotrophic lateral sclerosis: a systematic review. BMC Neurol (2016) 0.78
Is early-life iron exposure critical in neurodegeneration? Nat Rev Neurol (2015) 0.78
Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease. Curr Neuropharmacol (2016) 0.77
Brain Iron Metabolism Dysfunction in Parkinson's Disease. Mol Neurobiol (2016) 0.77
The role of iron in neurodegenerative disorders: insights and opportunities with synchrotron light. Front Pharmacol (2014) 0.77
Alpha-synuclein and iron: two keys unlocking Parkinson's disease. J Neural Transm (Vienna) (2017) 0.76
Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. Chem Rev (2017) 0.76
Parkinson's Disease: The Mitochondria-Iron Link. Parkinsons Dis (2016) 0.76
Iron Chelators and Antioxidants Regenerate Neuritic Tree and Nigrostriatal Fibers of MPP+/MPTP-Lesioned Dopaminergic Neurons. PLoS One (2015) 0.76
Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges. J Clin Neurol (2016) 0.76
Unified theory of Alzheimer's disease (UTAD): implications for prevention and curative therapy. J Mol Psychiatry (2016) 0.76
The clinical effect of deferoxamine mesylate on edema after intracerebral hemorrhage. PLoS One (2015) 0.76
Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease. J Neurol Sci (2017) 0.76
Excessive early-life dietary exposure: a potential source of elevated brain iron and a risk factor for Parkinson's disease. NPJ Parkinsons Dis (2017) 0.76
Structure, Distribution, and Genetic Profile of α-Synuclein and Their Potential Clinical Application in Parkinson's Disease. J Mov Disord (2017) 0.75
Rationale for the Successful Management of EDTA Chelation Therapy in Human Burden by Toxic Metals. Biomed Res Int (2016) 0.75
Iron overload induced death of osteoblasts in vitro: involvement of the mitochondrial apoptotic pathway. PeerJ (2016) 0.75
Sarcandra glabra (Caoshanhu) protects mesenchymal stem cells from oxidative stress: a bioevaluation and mechanistic chemistry. BMC Complement Altern Med (2016) 0.75
Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View. Curr Neuropharmacol (2016) 0.75
Magnetic Resonance Imaging Features of the Nigrostriatal System: Biomarkers of Parkinson's Disease Stages? PLoS One (2016) 0.75
Preferential Extracellular Generation of the Active Parkinsonian Toxin MPP(+) by Transporter-Independent Export of the Intermediate MPDP(.). Antioxid Redox Signal (2015) 0.75
Metals and neurodegeneration. Neurobiol Dis (2015) 0.75
Revisiting Metal Toxicity in Neurodegenerative Diseases and Stroke: Therapeutic Potential. Neurol Res Ther (2015) 0.75
Clinical quantitative susceptibility mapping (QSM): Biometal imaging and its emerging roles in patient care. J Magn Reson Imaging (2017) 0.75
α-Synuclein impairs ferritinophagy in the retinal pigment epithelium: Implications for retinal iron dyshomeostasis in Parkinson's disease. Sci Rep (2017) 0.75
A novel iron (II) preferring dopamine agonist chelator D-607 significantly suppresses α-syn- and MPTP-induced toxicities in vivo. Neuropharmacology (2017) 0.75
Subcellular compartmentalisation of copper, iron, manganese, and zinc in the Parkinson's disease brain. Metallomics (2017) 0.75
Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov (2017) 0.75
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
Oxidative stress and neurodegeneration: where are we now? J Neurochem (2006) 5.44
Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci (2004) 5.37
Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature (2010) 4.07
Iron overload in human disease. N Engl J Med (2012) 3.77
Transient and long-lasting openings of the mitochondrial permeability transition pore can be monitored directly in intact cells by changes in mitochondrial calcein fluorescence. Biophys J (1999) 2.96
Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat Rev Mol Cell Biol (2008) 2.92
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron (2003) 2.80
Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol (2006) 2.39
Anemia or low hemoglobin levels preceding Parkinson disease: a case-control study. Neurology (2009) 2.09
Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain (2010) 2.01
Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol (2007) 1.85
Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood (2007) 1.84
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood (2005) 1.62
Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains. J Neurosci Res (1990) 1.60
Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol (2003) 1.57
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol (2013) 1.56
The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann N Y Acad Sci (2003) 1.53
Glutathione--a review on its role and significance in Parkinson's disease. FASEB J (2009) 1.50
Profile of altered brain iron acquisition in restless legs syndrome. Brain (2011) 1.48
Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat Rev Neurosci (2013) 1.46
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood (2003) 1.46
Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord (2011) 1.44
Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood (2007) 1.44
Intracellular labile iron. Int J Biochem Cell Biol (2007) 1.42
Increased nigral iron content in postmortem parkinsonian brain. Lancet (1987) 1.39
Iron regulatory proteins: from molecular mechanisms to drug development. Antioxid Redox Signal (2010) 1.35
A review of fluorescence methods for assessing labile iron in cells and biological fluids. Anal Biochem (2002) 1.34
Relaxation induced by ferritin: a better understanding for an improved MRI iron quantification. NMR Biomed (2004) 1.33
Rapid, complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line. J Neurochem (2011) 1.27
Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem (2005) 1.27
MRI assessment of basal ganglia iron deposition in Parkinson's disease. J Magn Reson Imaging (2008) 1.23
Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Cerebellum (2011) 1.21
The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord (1993) 1.15
Study of brain anatomy with high-field MRI: recent progress. Magn Reson Imaging (2010) 1.14
Ferritin and ferritin isoforms I: Structure-function relationships, synthesis, degradation and secretion. Arch Physiol Biochem (2007) 1.11
A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica (2011) 1.10
NMR spectroscopy metabolomic profiling of exhaled breath condensate in patients with stable and unstable cystic fibrosis. Thorax (2011) 1.07
On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. J Cardiovasc Magn Reson (2011) 1.05
Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. J Biol Chem (2009) 1.03
Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation. Can J Physiol Pharmacol (2010) 1.01
Mitochondrial iron metabolism and its role in neurodegeneration. J Alzheimers Dis (2010) 1.01
Mitochondrial Ca2+ transients in cardiac myocytes during the excitation-contraction cycle: effects of pacing and hormonal stimulation. J Bioenerg Biomembr (1998) 0.99
Non-transferrin-bound iron reaches mitochondria by a chelator-inaccessible mechanism: biological and clinical implications. Am J Physiol Cell Physiol (2007) 0.98
Deferiprone chelation therapy for thalassemia major. Acta Haematol (2009) 0.97
Iron metabolism and mitochondrial abnormalities in Friedreich ataxia. Blood Cells Mol Dis (2003) 0.97
Identification of nonferritin mitochondrial iron deposits in a mouse model of Friedreich ataxia. Proc Natl Acad Sci U S A (2012) 0.97
H-ferritin is the major source of iron for oligodendrocytes. Glia (2011) 0.96
Chelators in the treatment of iron accumulation in Parkinson's disease. Int J Cell Biol (2012) 0.95
Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxid Redox Signal (2010) 0.93
Inhibition of catechol-O-methyltransferase (COMT) as well as tyrosine and tryptophan hydroxylase by the orally active iron chelator, 1,2-dimethyl-3-hydroxypyridin-4-one (L1, CP20), in rat brain in vivo. Biochem Pharmacol (1993) 0.90
Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells. J Neurochem (2008) 0.89
Iron chelation and neuroprotection in neurodegenerative diseases. J Neural Transm (Vienna) (2010) 0.89
Rescuing iron-overloaded macrophages by conservative relocation of the accumulated metal. Br J Pharmacol (2011) 0.89
Biomonitoring of the adverse effects induced by the chronic exposure to lead and cadmium on kidney function: usefulness of alpha-glutathione S-transferase. Sci Total Environ (2007) 0.89
Increased oxidative damage in peripheral blood correlates with severity of Parkinson's disease. Neurobiol Dis (2008) 0.89
Oxidation chemistry of catecholamines and neuronal degeneration: an update. Curr Med Chem (2011) 0.88
Targeting mitochondria for neuroprotection in Parkinson's disease. Antioxid Redox Signal (2012) 0.88
The potential application of iron chelators for the treatment of neurodegenerative diseases. Metallomics (2011) 0.87
Increased sensitivity of striatal dopamine release to H2O2 upon chronic rotenone treatment. Free Radic Biol Med (2005) 0.86
Dunkerque City air pollution particulate matter-induced cytotoxicity, oxidative stress and inflammation in human epithelial lung cells (L132) in culture. Toxicol In Vitro (2005) 0.85
Mitochondrial mayhem: the mitochondrion as a modulator of iron metabolism and its role in disease. Antioxid Redox Signal (2011) 0.85
Modulation of somatodendritic dopamine release by endogenous H(2)O(2): susceptibility in substantia nigra but resistance in VTA. J Neurophysiol (2002) 0.85
Chelating agents for the treatment of systemic iron overload. Curr Med Chem (2012) 0.85
Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. J Neural Transm (Vienna) (2010) 0.83
High-performance liquid chromatography/tandem mass spectrometry assay for the determination of 1-methyl-4-phenyl pyridinium (MPP+) in brain tissue homogenates. J Neurosci Methods (2004) 0.82
Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease. Pharmacol Res (2012) 0.82
X-ray fluorescence analysis of iron and manganese distribution in primary dopaminergic neurons. J Neurochem (2012) 0.82
Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model. Exp Neurol (2013) 0.81
The mitochondrial dynamics of Alzheimer's disease and Parkinson's disease offer important opportunities for therapeutic intervention. Curr Pharm Des (2011) 0.81
Polycyclic aromatic hydrocarbon coated onto Fe(2)O(3) particles: assessment of cellular membrane damage and antioxidant system disruption in human epithelial lung cells (L132) in culture. Toxicol Lett (2000) 0.80
Does structural neuroimaging reveal a disturbance of iron metabolism in Parkinson's disease? Implications from MRI and TCS studies. J Neural Transm (Vienna) (2012) 0.80
Early liver transplantation for severe alcoholic hepatitis. N Engl J Med (2011) 8.50
Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet (2004) 7.69
Validation of the paediatric logistic organ dysfunction (PELOD) score: prospective, observational, multicentre study. Lancet (2003) 5.40
Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med (2005) 3.88
Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc Natl Acad Sci U S A (2004) 3.87
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood (2012) 3.44
Lysosomes in cell death. Oncogene (2004) 3.00
A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65
Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3 year follow-up study. Lancet Neurol (2007) 2.61
Cumulative influence of organ dysfunctions and septic state on mortality of critically ill children. Am J Respir Crit Care Med (2004) 2.56
The labile iron pool: characterization, measurement, and participation in cellular processes(1). Free Radic Biol Med (2002) 2.51
Safety and effectiveness of gadolinium-enhanced multi-detector row spiral CT angiography of the chest: preliminary results in 37 patients with contraindications to iodinated contrast agents. Radiology (2005) 2.40
Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 2.28
Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Hum Mol Genet (2010) 2.21
Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol (2012) 2.17
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology (2013) 2.06
Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification. Neurology (2012) 2.05
Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med (2010) 2.04
Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients. Br J Haematol (2013) 2.03
Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification. Brain (2013) 2.02
Polyunsaturated fatty acids are cerebral vasodilators via the TREK-1 potassium channel. Circ Res (2007) 2.02
Parsing molecular and behavioral effects of cocaine in mitogen- and stress-activated protein kinase-1-deficient mice. J Neurosci (2005) 2.01
A new approach to corpus callosum anomalies in idiopathic scoliosis using diffusion tensor magnetic resonance imaging. Eur Spine J (2014) 2.01
Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet (2011) 2.00
Calculation of electron dose to target cells in a complex environment by Monte Carlo code "CELLDOSE". Eur J Nucl Med Mol Imaging (2008) 1.97
The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. ALTEX (2009) 1.97
Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 1.94
Sexuality and obesity, a gender perspective: results from French national random probability survey of sexual behaviours. BMJ (2010) 1.94
Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA (2013) 1.94
Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood (2003) 1.93
Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A (2003) 1.88
Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study. Lancet Neurol (2009) 1.87
Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood (2007) 1.84
International prognostic scoring system for Waldenstrom macroglobulinemia. Blood (2009) 1.81
Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci (2003) 1.78
Multi-detector row spiral CT angiography of the thoracic outlet: dose reduction with anatomically adapted online tube current modulation and preset dose savings. Radiology (2003) 1.75
Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies. J Clin Oncol (2012) 1.74
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica (2009) 1.73
Determinants of and disparities in reproductive health service use among adolescent and young adult women in the United States, 2002-2008. Am J Public Health (2011) 1.72
Pulmonary arteriovenous malformations treated with embolotherapy: helical CT evaluation of long-term effectiveness after 2-21-year follow-up. Radiology (2006) 1.70
Evaluation of developmental toxicants and signaling pathways in a functional test based on the migration of human neural crest cells. Environ Health Perspect (2012) 1.70
High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol (2006) 1.68
Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. Hum Mol Genet (2010) 1.67
Posterior fossa volume increase after surgery for Chiari malformation Type I: a quantitative assessment using magnetic resonance imaging and correlations with the treatment response. J Neurosurg (2011) 1.62
Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood (2005) 1.62
Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol (2012) 1.61
Activation of peroxisome proliferator-activated receptor-alpha by fenofibrate prevents myocardial dysfunction during endotoxemia in rats. Crit Care Med (2007) 1.57
The dynamics of the LPS triggered inflammatory response of murine microglia under different culture and in vivo conditions. J Neuroimmunol (2006) 1.57
Assessment of non-small cell lung cancer perfusion: pathologic-CT correlation in 15 patients. Radiology (2010) 1.56
Chest computed tomography using iterative reconstruction vs filtered back projection (Part 2): image quality of low-dose CT examinations in 80 patients. Eur Radiol (2010) 1.56
Stroke prevention: management of modifiable vascular risk factors. J Neurol (2002) 1.55
Operational lumped constant for FDG in normal adult male rats. J Nucl Med (2007) 1.54
Parkinson's disease dementia can be easily detected in routine clinical practice. Mov Disord (2010) 1.53
Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J Neurosci (2003) 1.53
The significance of cortical cerebellar microbleeds and microinfarcts in neurodegenerative and cerebrovascular diseases. A post-mortem 7.0-tesla magnetic resonance study with neuropathological correlates. Cerebrovasc Dis (2015) 1.53
Comparison of the Farr radioimmunoassay, 3 commercial enzyme immunoassays and Crithidia luciliae immunofluorescence test for diagnosis and activity assessment of systemic lupus erythematosus. Clin Chim Acta (2010) 1.52
Lipid profiles and outcome in patients treated by intravenous thrombolysis for cerebral ischemia. Neurology (2012) 1.51
Anti-p200 pemphigoid: a novel autoimmune subepidermal blistering disease. J Dermatol (2007) 1.49
Study of mitochondrial membrane potential, reactive oxygen species, DNA fragmentation and cell viability by flow cytometry in human sperm. Hum Reprod (2002) 1.48
An analysis of the biochemical diagnosis of 66 pheochromocytomas. Eur J Endocrinol (2007) 1.47
Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. Leuk Res (2010) 1.47
Teenage pregnancies in the European Union in the context of legislation and youth sexual and reproductive health services. Acta Obstet Gynecol Scand (2013) 1.46
Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res (2010) 1.46
Effects of sitting position and applied positive end-expiratory pressure on respiratory mechanics of critically ill obese patients receiving mechanical ventilation*. Crit Care Med (2013) 1.46
Early dopasensitive Parkinsonism related to myotonic dystrophy type 2. Mov Disord (2008) 1.46
Expression of apoptosis regulatory factors during myocardial dysfunction in endotoxemic rats. Crit Care Med (2005) 1.46
Rapid eye movement sleep behavior disorder in treatment-naïve Parkinson disease patients. Sleep Med (2013) 1.45
Paediatric logistic organ dysfunction (PELOD) score. Lancet (2006) 1.45
Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood (2007) 1.44
How much phenotypic variation can be attributed to parkin genotype? Ann Neurol (2003) 1.44
Caspase-dependent protein phosphatase 2A activation contributes to endotoxin-induced cardiomyocyte contractile dysfunction. Crit Care Med (2010) 1.43
Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia. Blood (2012) 1.43
Toxicogenomics directory of chemically exposed human hepatocytes. Arch Toxicol (2014) 1.43
Intracellular labile iron. Int J Biochem Cell Biol (2007) 1.42
Mucinous carcinoma of the skin, primary, and secondary: a clinicopathologic study of 63 cases with emphasis on the morphologic spectrum of primary cutaneous forms: homologies with mucinous lesions in the breast. Am J Surg Pathol (2005) 1.42
Hsp27 consolidates intracellular redox homeostasis by upholding glutathione in its reduced form and by decreasing iron intracellular levels. Antioxid Redox Signal (2005) 1.41
Endotoxin-induced myocardial dysfunction: evidence for a role of sphingosine production. Crit Care Med (2004) 1.41
Eradication of glioblastoma, and breast and colon carcinoma xenografts by Hsp70 depletion. Cancer Res (2002) 1.40
Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann Neurol (2011) 1.40
Role of the ERK pathway in psychostimulant-induced locomotor sensitization. BMC Neurosci (2006) 1.39
Pathological apoptosis in the developing brain. Apoptosis (2007) 1.38
Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest (2005) 1.38
Chest computed tomography using iterative reconstruction vs filtered back projection (Part 1): Evaluation of image noise reduction in 32 patients. Eur Radiol (2010) 1.35
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica (2012) 1.35
Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy. Brain (2012) 1.34